In a recently published study, researchers have presented new evidence suggesting that oral contraceptives containing drospirenone result in a greater than 2-fold increased odds of developing non-fatal, idiopathic venous thromboembolism compared to current users of products containing levonorgestrel.
In a study published recently in the British Medical Journal, researchers presented new evidence suggesting oral contraceptives containing drospirenone result in a greater than 2-fold increased odds of developing non-fatal, idiopathic venous thromboembolism (VTE) compared to current users of products containing levonorgestrel.
Levonorgestrel, the most commonly prescribed progestin in the United States, can be found in multiple monophasic and multiphasic oral contraceptives, in emergency contraception (Plan B), and intrauterine devices (Mirena). Drospirenone, a newer, fourth-generation progestin, is currently found in the oral contraceptives Yaz, Yasmin, Yasminelle, and Beyaz.
In order to conduct their analysis, researchers from the Boston Collaborative Drug Surveillance Program and the Boston University School of Medicine examined the PharMetrics database which collects information on claims paid by US managed care plans. This analysis included all women aged 15 to 44 years who received an oral contraceptive containing either drospirenone or levonorgestrel starting from January 2002 forward. Cases were defined as women with current use of 1 of the 2 oral contraceptives and a diagnosis of idiopathic (no identifiable clinical risk factors present) VTE. Cases were matched to up to 4 control patients not experiencing VTE.
Of note, however, the overall risk of developing VTE in such patients was determined to be low. The crude incidence rate was 30.8 per 100,000 woman years in current users of drospirenone and 12.5 per 100,000 woman years in current users of levonorgestrel oral contraceptives. This corresponded to an age-adjusted incidence rate ratio of 2.8 (95% CI, 2.1–3.8).
Researchers also conducted secondary analyses to evaluate the effect of these 2 progestins on the risks of deep vein thrombosis and pulmonary embolism separately. The matched adjusted odds ratios for deep vein thrombosis and pulmonary embolism with drospirenone compared to levonorgestrel were 1.9 (95% CI, 1.1–3.2) and 2.6 (95% CI, 1.6–4.2), respectively.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.